JHVEPhoto/iStock Editorial by way of Getty Photographs
Pfizer (NYSE:PFE) Chief Monetary Officer David Denton reiterated that he expects the $43 billion acquisition of Seagen (NASDAQ:SGEN) to shut both later this yr or early subsequent yr because the deal awaits approval from the Federal Commerce Fee.
Pfizer (PFE) is working “diligently” to shut the Seagen (SGEN) deal, Denton mentioned at Evercore ISS’s sixth Annual HealthConx Convention on Tuesday.
“Clearly we proceed to work with them (FTC), but it surely’s somewhat little bit of a black field as all these offers are like that,” Denton mentioned.
Earlier this month, CNBC’s David Faber reported that Pfizer (PFE) might file substantial compliance with the FTC’s second request on the Seagen (SGEN) transaction in three to 4 weeks.
The Pfizer CEO reiterated late final month that he expects the deal will shut earlier than the tip of the yr or early subsequent yr. The European antitrust regulator accepted the Seagen (SGEN) buy final month.